Dr. Oliver Sartor on Doubling the Dosage of Radium-223 in Patients With CRPC

Video

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses how radium-223 dichloride became deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC). The treatment was tested in an open-label phase I/II trial where patients were given 6 additional doses of radium-223 on top of their original 6-dose regimen.

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses how radium-223 dichloride became deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC). The treatment was tested in an open-label phase I/II trial where patients were given 6 additional doses of radium-223 on top of their original 6-dose regimen.

Recent Videos
Related Content